Clinical performance data of Cervista HPV HR presented at International Papillomaviru

[News]

Hologic, Inc., a leading women's healthcare company, today announced that final data analysis from the first large-scale independent evaluation of clinical performance of Cervista HPV HR compared to Hybrid Capture 2, were presented in Montreal, Canada, at the 26th International Papillomavirus Conference. Cervista HPV HR is a diagnostic test for the detection of 14 high-risk human papillomavirus types.

More... (http://www.news-medical.net/news/20100708/Clinical-performance-data-of-Cervista-HPV-HR-presented-at-International-Papillomavirus-Conference.aspx)